The US Environmental Protection Agency has approved an RNAi-based insecticide, according to the Atlantic.
Under the terms of the deals, Illumina and Monsanto will have access to NRGene's genome assembly and analysis technologies for ag-bio research projects.
CRISPR/Cpf1 can serve as an alternative or even complementary genome editing technology to CRISPR/Cas9, which Monsanto has also licensed from the Broad.
The technology is based on engineered zinc finger DNA-binding proteins, which bind to specific functional domains to create transcription factors capable of activating or repressing target genes.
The ag-bio giant has landed a worldwide, non-exclusive licensing deal for agricultural applications of the genome-editing technology.
The partners will use their respective genome databases, bioinformatics tools, and other resources to identify new proteins for pest control.
The ag-bio giant has also taken an equity position in privately held, Rehovot, Israel-based TargetGene.
The findings further point to the importance of the stability and dosage of RNAi molecules to gene silencing in environmental RNAi-sensitive insects.
The program is part of the company's BioDirect initiative, which relates to the use of topically applied RNAi-based treatments for pest, weed, and disease control in crop plants.
The study examined high concentrations of consumed siRNAs and dsRNAs targeting the mouse ortholog of a known pest-control gene.
The president of France's National Research Agency has resigned, according to Nature News.
A senator wants a "right-to-try" provision in the US Food and Drug Administration funding bill, but an ethicist says at Stat News that it would undermine the role of clinical trials.
In PNAS this week: red algae Porphyra umbicalis genome, deep neural network model for sequencing peptides, and more.
The Guardian's Barbara Ellen has tried out some DNA testing services to see whether they provide valuable information.